Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta‐analysis of observational studies

dc.contributor.authorTang, Huilin
dc.contributor.authorFu, Shuangshuang
dc.contributor.authorZhai, Suodi
dc.contributor.authorSong, Yiqing
dc.contributor.authorAsgari, Maryam M.
dc.contributor.authorHan, Jiali
dc.contributor.departmentEpidemiology, School of Public Healthen_US
dc.date.accessioned2018-06-15T18:11:55Z
dc.date.available2018-06-15T18:11:55Z
dc.date.issued2018-03
dc.description.abstractPurpose Current epidemiologic evidence on the association between antihypertensive drugs and keratinocyte carcinoma (KC) risk is inconsistent. We sought to quantify this association by meta‐analysis of observational studies. Methods We systematically reviewed observational studies published through August 2016 and reported the KC risk (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) associated with antihypertensive drugs, including diuretics, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta‐adrenergic blocking agents (β‐blockers), and calcium channel blockers (CCBs). Random‐effects meta‐analysis was used to estimate the odds ratio (OR) with 95% confidence interval (CI). Results Ten eligible studies were included. Compared with nonuse, diuretic use was significantly associated with increased risk of both BCC (OR, 1.10; 95% CI, 1.01‐1.20) and SCC (OR, 1.40; 95% CI, 1.19‐1.66). Use of β‐blockers or CCBs was associated with increased risk of BCC (but not SCC); the OR with β‐blockers was 1.09 (95% CI, 1.04‐1.15) and with CCBs was 1.15 (95% CI, 1.09‐1.21). Use of ACE inhibitors or ARBs was associated with decreased risk of both BCC (OR, 0.53; 95% CI, 0.39‐0.71) and SCC (OR, 0.58; 95% CI, 0.42‐0.80) in high‐risk individuals. Conclusions Current evidence indicates that use of diuretics might be associated with increased risk of KC, while ACE inhibitors or ARBs might be associated with decreased risk in high‐risk individuals. β‐blockers or CCBs might be positively associated with BCC risk. Further postmarketing surveillance studies and investigations to clarify the possible underlying mechanisms are warranted.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationTang, H., Fu, S., Zhai, S., Song, Y., Asgari, M. M., & Han, J. (2018). Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety, 27(3), 279–288. https://doi.org/10.1002/pds.4384en_US
dc.identifier.urihttps://hdl.handle.net/1805/16533
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/pds.4384en_US
dc.relation.journalPharmacoepidemiology and Drug Safetyen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectantihypertensive drugsen_US
dc.subjectkeratinocyte carcinomaen_US
dc.subjectbasal cell carcinomaen_US
dc.titleUse of antihypertensive drugs and risk of keratinocyte carcinoma: A meta‐analysis of observational studiesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Tang_2018_Antihypertensive.pdf
Size:
747.29 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: